BioSpace News Archive

As part of its global response to the COVID-19 pandemic, International Medical Corps has deployed emergency medical field units, personal protective equipment and volunteer clinicians to Vista Medical Center East.

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced an agreement for a commitment of up to $483 million from the Biomedical Advanced Research and Development Authority (BARDA),

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will issue a press release on its first quarter financial results on Thursday, May 7, 2020 at 7:00 a.m. ET.

Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC: MMEDF), the leading psychedelic pharmaceutical company, has begun dosing the first subject in an additional Phase 1 human safety trial of 18-MC.

Kraig Biocraft Laboratories, Inc., the leading developer of spider silk based fibers, announced, at a press conference held after today’s market close, that it successfully developed a new technology platform, based on a non-CRISPR gene editing knock-in knock-out technology.

ViewRay, Inc. (Nasdaq: VRAY) announced the appointment of B. Kristine Johnson to its Board of Directors effective April 14, 2020.

Accelerates the detection and identification of viral sequences and seamless submission to critical databases

Cutera, Inc. (NASDAQ: CUTR) (“Cutera”), a provider of laser and other energy-based aesthetic systems for practitioners worldwide, today announced that it has commenced an underwritten public offering of its common stock. In connection with the offering, Cutera intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the offering. All of the shares in the

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its first quarter 2020 investor update conference call and webcast at 4:30 p.m. Eastern Time on Wednesday, May 6, 2020. Individuals interested in participating in the call should dial (866) 393-4306 (U.S. and Canada) or (734) 385-2616 (international) using conference ID number 5494696. To access the webcast, please visit the Investors section of Ironwoo

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced that it has closed its previously announced registered direct offering of 750,000 shares of its common st